When Novartis completed its $9.7 billion acquisition of The Medicines Company in early January, it capped a more than four-year activist campaign by Sarissa Capital Management to push for changes at the target company.
It was well worth the long effort.
Novartis paid a 45 percent premium for The Medicines Company’s shares, which quadrupled in price last year.
